Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Hanne Due"'
Autor:
Emil Aagaard Thomsen, Anne Bruun Rovsing, Mads Valdemar Anderson, Hanne Due, Jinrong Huang, Yonglun Luo, Karen Dybkær, Jacob Giehm Mikkelsen
Publikováno v:
Molecular Oncology, Vol 14, Iss 9, Pp 1978-1997 (2020)
Diffuse large B‐cell lymphoma (DLBCL) is characterized by extensive genetic heterogeneity, and this results in unpredictable responses to the current treatment, R‐CHOP, which consists of a cancer drug combination supplemented with the humanized C
Externí odkaz:
https://doaj.org/article/db68e49e73e744989b9cfb52fe01b91f
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-12 (2020)
Abstract Background Treatment resistance is a major clinical challenge of diffuse large B-cell lymphoma (DLBCL) where approximately 40% of the patients have refractory disease or relapse. Since DLBCL is characterized by great clinical and molecular h
Externí odkaz:
https://doaj.org/article/b8264806fd2342fd8e3da2f8cab719ff
Autor:
Linnéa Schmidt, Issa Ismail Issa, Hulda Haraldsdóttir, Jonas Laugård Hald, Alexander Schmitz, Hanne Due, Karen Dybkær
Publikováno v:
Schmidt, L, Issa, I I, Haraldsdóttir, H, Hald, J L, Schmitz, A, Due, H & Dybkær, K 2022, ' Hsp90 inhibition sensitizes DLBCL cells to cisplatin ', Cancer Chemotherapy and Pharmacology, vol. 89, no. 4, pp. 431-440 . https://doi.org/10.1007/s00280-022-04407-5
Schmidt, L, Issa, I I, Haraldsdóttir, H, Hald, J L, Due, H & Dybkær, K 2022, ' Hsp90 inhibition sensitizes DLBCL cells to cisplatin ', Cancer Chemotherapy and Pharmacology, vol. 89, no. 4, pp. 431-440 . https://doi.org/10.1007/s00280-022-04407-5
Schmidt, L, Issa, I I, Haraldsdóttir, H, Hald, J L, Due, H & Dybkær, K 2022, ' Hsp90 inhibition sensitizes DLBCL cells to cisplatin ', Cancer Chemotherapy and Pharmacology, vol. 89, no. 4, pp. 431-440 . https://doi.org/10.1007/s00280-022-04407-5
PurposePlatinum-containing therapy is standard treatment for relapsed Diffuse Large B-Cell Lymphoma (DLBCL). However, the efficacy of treatment is limited by drug resistance leading to relapse. Cisplatin resistance has been linked to impairments of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95c3d1875eb090fc0377fa24b24ad23b
https://vbn.aau.dk/ws/files/468426671/Schmidt_et_al._2022_._Hsp90_inhibition_sensitizes_DLBCL_cells_to_cisplatin.pdf
https://vbn.aau.dk/ws/files/468426671/Schmidt_et_al._2022_._Hsp90_inhibition_sensitizes_DLBCL_cells_to_cisplatin.pdf
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-12 (2020)
BMC Cancer
Due, H, Brøndum, R F, Young, K H, Bøgsted, M & Dybkær, K 2020, ' MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index ', BMC Cancer, vol. 20, no. 1, 237 . https://doi.org/10.1186/s12885-020-6643-8
BMC Cancer
Due, H, Brøndum, R F, Young, K H, Bøgsted, M & Dybkær, K 2020, ' MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index ', BMC Cancer, vol. 20, no. 1, 237 . https://doi.org/10.1186/s12885-020-6643-8
Background Treatment resistance is a major clinical challenge of diffuse large B-cell lymphoma (DLBCL) where approximately 40% of the patients have refractory disease or relapse. Since DLBCL is characterized by great clinical and molecular heterogene
Publikováno v:
Cancer Chemotherapy and Pharmacology
Madsen, M L, Due, H, Ejskjær, N, Jensen, P, Madsen, J & Dybkær, K 2019, ' Aspects of vincristine-induced neuropathy in hematologic malignancies : a systematic review ', Cancer Chemotherapy and Pharmacology, vol. 84, no. 3, pp. 471–485 . https://doi.org/10.1007/s00280-019-03884-5
Madsen, M L, Due, H, Ejskjær, N, Jensen, P, Madsen, J & Dybkær, K 2019, ' Aspects of vincristine-induced neuropathy in hematologic malignancies : a systematic review ', Cancer Chemotherapy and Pharmacology, vol. 84, no. 3, pp. 471–485 . https://doi.org/10.1007/s00280-019-03884-5
Purpose Vincristine is widely used as anticancer therapy for a variety of hematological malignancies. The treatment is limited by progressive vincristine-induced neuropathy, possibly including both peripheral sensory and motor nerves, autonomic nervo
Autor:
Maria Nascimento Primo, Emil Aagaard Thomsen, Xiaohong Tan, Ditte Starberg Jespersen, Anna Amanda Schönherz, Laura Barrett Ryø, Hanne Due, Martin Bøgsted, Karen Dybkær, Jacob Giehm Mikkelsen, Yuyang Pang, Anne Stidholt Roug, Ken H. Young, Min Xiao
Publikováno v:
Due, H, Schönherz, A A, Ryø, L, Primo, M N, Jespersen, D S, Thomsen, E A, Roug, A S, Xiao, M, Tan, X, Pang, Y, Young, K H, Bøgsted, M, Mikkelsen, J G & Dybkær, K 2019, ' MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma ', Blood advances, vol. 3, no. 7, pp. 1185-1196 . https://doi.org/10.1182/bloodadvances.2018029660
Due, H, Schönherz, A A, Ryø, L, Primo, M N, Jespersen, D S, Thomsen, E A, Roug, A S, Xiao, M, Tan, X, Pang, Y, Young, K H, Bøgsted, M, Mikkelsen, J G & Dybkær, K 2019, ' MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma ', Blood Advances, vol. 3, no. 7, pp. 1185-1196 . https://doi.org/10.1182/bloodadvances.2018029660
Due, H, Schönherz, A A, Ryø, L, Primo, M N, Jespersen, D S, Thomsen, E A, Roug, A S, Xiao, M, Tan, X, Pang, Y, Young, K H, Bøgsted, M, Mikkelsen, J G & Dybkær, K 2019, ' MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma ', Blood Advances, vol. 3, no. 7, pp. 1185-1196 . https://doi.org/10.1182/bloodadvances.2018029660
A major clinical challenge of diffuse large B-cell lymphoma (DLBCL) is that up to 40% of patients have refractory disease or relapse after initial response to therapy as a result of drug-specific molecular resistance. The purpose of the present study
Autor:
Ditte Starberg Jespersen, Julie Støve Bødker, Steffen Falgreen, Suzette Sørensen, Hans Erik Johnsen, Maria Bach Laursen, Martin Bøgsted, Karen Dybkær, Anna Amanda Schönherz, Linn Reinholdt, Hanne Due, Marianne Schmidt Ettrup, Rasmus Røge, Alexander Schmitz, Lykke Christina Grubach
Publikováno v:
Laursen, M B, Reinholdt, L, Schönherz, A A, Due, H, Jespersen, D S, Grubach, L, Ettrup, M S, Røge, R, Falgreen, S, Sørensen, S, Bødker, J S, Schmitz, A, Johnsen, H E, Bøgsted, M & Dybkær, K 2019, ' High CXCR4 expression impairs rituximab response and the prognosis of R-CHOP-treated diffuse large B-cell lymphoma patients ', Oncotarget, vol. 10, no. 7, pp. 717-731 . https://doi.org/10.18632/oncotarget.26588
Laursen, M B, Reinholdt, L, Schönherz, A A, Due, H, Jespersen, D S, Grubach, L, Ettrup, M S, Røge, R, Falgreen, S, Sørensen, S, Bødker, J S, Schmitz, A, Johnsen, H E, Bøgsted, M & Dybkær, K 2019, ' High CXCR4 expression impairs rituximab response and the prognosis of R-CHOP-treated diffuse large B-cell lymphoma patients ' OncoTarget, vol. 10, no. 7, pp. 717-731 . https://doi.org/10.18632/oncotarget.26588
Oncotarget
Laursen, M B, Reinholdt, L, Schönherz, A A, Due, H, Jespersen, D S, Grubach, L, Ettrup, M S, Røge, R, Falgreen, S, Sørensen, S, Bødker, J S, Schmitz, A, Johnsen, H E, Bøgsted, M & Dybkær, K 2019, ' High CXCR4 expression impairs rituximab response and the prognosis of R-CHOP-treated diffuse large B-cell lymphoma patients ' OncoTarget, vol. 10, no. 7, pp. 717-731 . https://doi.org/10.18632/oncotarget.26588
Oncotarget
Survival of diffuse large B-cell lymphoma (DLBCL) patients has improved by inclusion of rituximab. Refractory/recurrent disease caused by treatment resistance is, however, a major problem. Determinants of rituximab sensitivity are not fully understoo
Autor:
Martin Bøgsted, Alice Linnéa Annie Matilda Schmidt, Rasmus Froberg Brøndum, Karen Dybkær, Issa Ismail Issa, Hanne Due
Publikováno v:
Issa, I I, Brøndum, R F, Due, H, Schmidt, A L A M, Bøgsted, M & Dybkær, K 2021, ' A bendamustine resistance gene signature in diffuse large B-cell lymphoma and multiple myeloma ', Cancer Drug Resistance, vol. 4, no. 1, pp. 208-222 . https://doi.org/10.20517/cdr.2020.76
Bendamustine is primarily used for treatment of indolent lymphomas but has shown efficacy in some patients with diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM). Molecular-based patient stratification for identification of resistant pa
Publikováno v:
Blood. 134:1623-1623
Background: Patients with Diffuse large B-cell lymphoma (DLBCL) in approximately 40% of cases suffer from primary refractory disease and treatment induced immuno-chemotherapy resistance demonstrating that standard provided treatment regimens are not
Autor:
Charlotte Pawlyn, Hanne Due, Mehmet Kemal Samur, Annemiek Broyl, Charles Vesteghem, Ditte Starberg Jespersen, Julie Støve Bødker, Uta Bertsch, Faith E. Davies, Anna Amanda Schönherz, Nikhil C. Munshi, Martin Agge Nørgaard, Martin Perez-Andres, Alberto Orfao, Gareth J. Morgan, Rasmus Froberg Brøndum, Tarec Christoffer El-Galaly, Martin Kaiser, Alexander Schmitz, Brian A Walker, Hans Erik Johnson, Pieter Sonneveld, Martin Bøgsted, Rajen D. Shah, Hartmut Goldschmidt, Mads Sønderkær, Karen Dybkær, Richard J. Samworth, Mark van Duin, Preben Johansen, Caroline Holm Nørgaard, David W. Johnson
Publikováno v:
Bødker, J S, Brøndum, R F, Schmitz, A, Schönherz, A A, Jespersen, D S, Sønderkær, M, Vesteghem, C, Due, H, Nørgaard, C H, Perez-Andres, M, Samur, M K, Davies, F, Walker, B, Pawlyn, C, Kaiser, M, Johnson, D, Bertsch, U, Broyl, A, van Duin, M, Shah, R, Johansen, P, Nørgaard, M A, Samworth, R J, Sonneveld, P, Goldschmidt, H, Morgan, G J, Orfao, A, Munshi, N, Johnsen, H E, El-Galaly, T, Dybkær, K & Bøgsted, M 2018, ' A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis ', Blood advances, vol. 2, no. 18, pp. 2400-2411 . https://doi.org/10.1182/bloodadvances.2018018564
Blood advances, 2(18), 2400-2411. American Society of Hematology
Bødker, J S, Brøndum, R F, Schmitz, A, Schönherz, A A, Jespersen, D S, Sønderkær, M, Vesteghem, C, Due, H, Nørgaard, C H, Perez-Andres, M, Samur, M K, Davies, F, Walker, B, Pawlyn, C, Kaiser, M, Johnson, D, Bertsch, U, Broyl, A, van Duin, M, Shah, R, Johansen, P, Nørgaard, M A, Samworth, R J, Sonneveld, P, Goldschmidt, H, Morgan, G J, Orfao, A, Munshi, N, Johnson, H E, El-Galaly, T, Dybkær, K & Bøgsted, M 2018, ' A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis ' Blood Advances, vol. 2, no. 18, pp. 2400-2411 . https://doi.org/10.1182/bloodadvances.2018018564
Blood advances, 2(18), 2400-2411. American Society of Hematology
Bødker, J S, Brøndum, R F, Schmitz, A, Schönherz, A A, Jespersen, D S, Sønderkær, M, Vesteghem, C, Due, H, Nørgaard, C H, Perez-Andres, M, Samur, M K, Davies, F, Walker, B, Pawlyn, C, Kaiser, M, Johnson, D, Bertsch, U, Broyl, A, van Duin, M, Shah, R, Johansen, P, Nørgaard, M A, Samworth, R J, Sonneveld, P, Goldschmidt, H, Morgan, G J, Orfao, A, Munshi, N, Johnson, H E, El-Galaly, T, Dybkær, K & Bøgsted, M 2018, ' A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis ' Blood Advances, vol. 2, no. 18, pp. 2400-2411 . https://doi.org/10.1182/bloodadvances.2018018564
Despite the recent progress in treatment of multiple myeloma (MM), it is still an incurable malignant disease, and we are therefore in need of new risk stratification tools that can help us to understand the disease and optimize therapy. Here we prop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e42706263254e82e9e883353b837adc9
https://vbn.aau.dk/da/publications/3aa38799-da66-45ad-8dbd-85e69ccdc4b9
https://vbn.aau.dk/da/publications/3aa38799-da66-45ad-8dbd-85e69ccdc4b9